Annual report pursuant to Section 13 and 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.22.4
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
12 Months Ended
Oct. 31, 2022
Oct. 31, 2021
Segment Reporting Information [Line Items]    
Net income (loss) $ (13,771) $ (13,128)
Total operating costs and expenses 13,875 13,648
Less non-cash share-based compensation (6,655) (8,058)
Operating costs and expenses excluding non-cash share based compensation 7,220 5,590
Total assets 30,412 36,257
CAR-T Therapeutics [Member]    
Segment Reporting Information [Line Items]    
Net income (loss) (5,776) (5,673)
Operating costs and expenses excluding non-cash share based compensation 3,206 2,422
Total assets 16,921 15,068
Cancer Vaccines [Member]    
Segment Reporting Information [Line Items]    
Net income (loss) (4,889) (4,559)
Operating costs and expenses excluding non-cash share based compensation 2,355 1,642
Total assets 9,442 13,277
Anti-Viral Therapeutics [Member]    
Segment Reporting Information [Line Items]    
Net income (loss) (3,075) (2,928)
Operating costs and expenses excluding non-cash share based compensation 1,634 1,080
Total assets 3,811 7,368
Other [Member]    
Segment Reporting Information [Line Items]    
Net income (loss) (31) 32
Operating costs and expenses excluding non-cash share based compensation 25 446
Total assets $ 238 $ 544